STAT

MARCH 1, 2024

CommonSpirit Health is hosting an educational event this month featuring RaDonda Vaught, the Tennessee nurse who was criminally prosecuted for accidentally killing a patient by injecting the wrong medication.

Hospitals 306

Hospitals 306

STAT

APRIL 27, 2023

Editor’s Note: A livestream of the event will be embedded below at 1 p.m. Each year, STAT chooses a new class of Wunderkinds, showcasing stars of science and medicine who are in the midst of launching their careers. Read the rest…

245

245

STAT

SEPTEMBER 17, 2024

Called “AI in Action: Transforming Health and Human Services,” the three-hour event is hosted by the federal health department. Federal health officials wrestling with when and how to use artificial intelligence will on Wednesday host an invitation-only meeting of AI leaders across industry, academia, and government.

Medical Schools 318

Medical Schools Hospitals 318

STAT

JANUARY 13, 2023

Editor’s note: A live stream of the event will be embedded below at 1 p.m. Relive the return to an in-person J.P. Morgan Healthcare Conference with the STAT reporters who attended. Get a full rundown of the deals, data, and scuttlebutt and come away with the ideas and water-cooler chatter you need for next week. Read the rest…

245

245

STAT

JUNE 20, 2024

The outcome of the HELIOS-B study — expected at the end of June or early July — is an enormous stock-moving event for Alnylam Pharmaceuticals. STAT+ subscribers can sign up  here  to get it delivered every Thursday to their inbox.

298

298

STAT

DECEMBER 14, 2022

Editor’s Note: A livestream of the event will be embedded below at 1 p.m.   Join  STAT for a discussion with industry experts on the most prominent work presented at this meeting and a look at what’s coming in hematology in the year ahead. Read the rest…

240

240

STAT

MAY 7, 2024

Editor’s note: A livestream of the event will be embedded below at 1 p.m. It took decades for scientists to come up with treatments that could slow the progression of Alzheimer’s disease. Now patients and physicians face a new challenge: actually getting the medicines to people who might benefit from them.

248

248

STAT

APRIL 2, 2024

Here is STAT’s biotech scoreboard, our regular ledger of stock-moving biotech events, for the second quarter and middle of the year: Obesity catalysts, first. Danish drugmaker Zealand Pharma — yes, there’s another Danish drug maker in obesity — is developing a long-acting amylin analog called petrelintide.

284

284

STAT

SEPTEMBER 25, 2023

Editor’s note: A livestream of the event will be embedded below at 1 p.m.   How do we ensure the population in a study best reflects the people who will get a medicine in the real world? Read the rest…

263

263

STAT

OCTOBER 2, 2024

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the fourth quarter: Rarely before has a large-cap biotech had so much riding on the outcome of a Phase 2 study as Amgen does with its obesity treatment MariTide , also known as AMG 133. Results are coming before the end of the year.

280

280

STAT

JANUARY 2, 2024

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter: In December, Vertex Pharmaceuticals announced results from a mid-stage clinical trial showing its experimental, non-opioid drug reduced pain in people with diabetes who have chronic pain.

Diabetes 280

Diabetes 280

STAT

SEPTEMBER 25, 2023

Editor’s note: A livestream of the event will be embedded below at 1 p.m.   How do we ensure the population in a study best reflects the people who will get a medicine in the real world? Read the rest…

256

256

STAT

JUNE 21, 2023

Editor’s note: A livestream of the event will be embedded below at 1 p.m. Pharmacy benefit managers are intermediaries that are supposed to negotiate lower drug costs. But does the system work for patients? And how can we fix it when it doesn’t? Read the rest…

Drug Pricing 245

Drug Pricing 245

STAT

DECEMBER 1, 2023

Editor’s note: A livestream of the event will be embedded below at 1 p.m. After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

269

269

STAT

JULY 18, 2023

Editor’s note: A livestream of the event will be embedded below at 1 p.m. Now that biosimilar versions of Humira are starting to arrive, what happens next? Will this finally prove the case that biosimilars can deliver on big health care savings? What key signals will indicate how biosimilars might be prescribed, or paid for?

Biosimilars 245

Biosimilars Drug Pricing 245

STAT

OCTOBER 2, 2023

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the fourth quarter: The Food and Drug Administration’s decision in June to grant conditional approval to a gene therapy for Duchenne muscular dystrophy was a watershed moment for the treatment of the neuromuscular disease, and a big win for its maker, (..)

295

295

STAT

JULY 2, 2024

H​​ere is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter: Late last month, Alnylam Pharmaceuticals reported positive, top-line results from its HELIOS-B clinical trial testing vutrisiran in an increasingly common heart disease called ATTR-CM.

270

270

STAT

MARCH 20, 2023

Editor’s note: A livestream on the event will be embedded below at 1 p.m. Physicians are burned out and overworked. Patients are having a difficult time seeing doctors quickly and understanding what specialists they can see. Read the rest…

206

206

STAT

MARCH 22, 2024

What happens when too many excellent, pioneering researchers enter a room? A little madness.

331

331

STAT

SEPTEMBER 30, 2022

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the fourth quarter: Arrowhead Pharmaceuticals and partner Takeda Pharmaceuticals are nearing the completion of a mid-stage, placebo-controlled clinical trial of an RNA-based drug called fazirsiran in patients with alpha-1 antitrypsin deficiency, or AATD, (..)

262

262

STAT

JUNE 9, 2023

Editor’s Note: A livestream of the event will be embedded below on Monday, June 12 at 1 p.m. ET Running a successful clinical trial is as much about execution as science, as companies and researchers must nail operational details from picking the right trial sites to ensuring patients remain in the study.

245

245

STAT

JANUARY 3, 2023

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter: Last year, a novel combination pill developed by Karuna Therapeutics reduced psychosis and related symptoms experienced by patients with schizophrenia, achieving the main goals of a late-stage clinical trial.

244

244

STAT

OCTOBER 12, 2022

Editor’s note: A livestream of the conversation will be embedded below at 1 p.m. Like approaching asteroids, major biosimilars for Humira and other drugs are finally due to hit the market in 2023. Read the rest…

Biosimilars 245

Biosimilars 245

STAT

JULY 31, 2024

CHICAGO — “Buttery Biscuits & Hot Honey Gravy,” mushroom jerky, soy chicken nuggets, strawberry champagne donuts, plant-based frozen yogurt and buñuelos, white cheddar cheese puffs, chocolatey cookie dippers, egg-free Spanish cheesecake, plant-based chorizo-style empanadas … I was at the annual gathering of food (..)

362

362

STAT

JANUARY 4, 2023

Continuing economic uncertainty and the threat of a recession are casting a pall over health tech in 2023 — a dramatic shift for an industry that enjoyed abundant funding in the pandemic’s early stages.

358

358

STAT

JULY 3, 2023

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter: Novo Nordisk is conducting a large clinical trial to prove that its GLP-1 drug Wegovy, in addition to helping people lose weight, also improves cardiovascular health.

Hospitals 246

Hospitals 246

STAT

APRIL 4, 2023

Health tech companies are still plagued by a sluggish funding environment and a wobbling economy this quarter. Already this year, the industry has seen  the demise of once-prominent mental health startup Mindstrong , and layoffs from the likes of Color and Cerebral.

Hospitals 307

Hospitals 307

STAT

JUNE 14, 2023

Endometriosis, a common gynecological condition, is one of health’s great mimickers. It can manifest as a variety of painful symptoms but evade detection on scans and examinations. And for the estimated 10% to 15% of women with endometriosis, it can take over a decade to get a diagnosis.

291

291

STAT

OCTOBER 31, 2023

The world’s hottest summer on record is now bleeding into the fall. Instead of enjoying a cool respite from the heat, millions of Americans started September enduring temperatures so high that schools were forced to close across the country.

291

291

STAT

OCTOBER 26, 2022

Editor’s note: A livestream of the conversation will be embedded below at 1 p.m. Data sharing is essential to developing everything from medicines to artificial intelligence-based tools, but often ulterior commercial motives corrupt it. Read the rest…

242

242

STAT

SEPTEMBER 29, 2022

Editor’s note: A livestream of the conversation will be embedded below at 1 p.m. Despite all of their promise, newer medicines, especially those based on advanced technologies, have been met with unprecedented challenges in scaling up manufacturing, quality control, and commercial launch. Read the rest…

251

251

STAT

DECEMBER 28, 2023

Morgan Healthcare Conference, the largest event of its kind, will take place in San Francisco, Jan. The event is a gathering space for investors, entrepreneurs, and others. Join us at the conference STAT will host an in-person event on Jan. Join us at the conference STAT will host an in-person event on Jan.

305

305

STAT

SEPTEMBER 25, 2024

Pfizer said Wednesday that it was removing Oxbryta, a pill for the treatment of sickle cell disease, from all markets globally due to high risks of severe safety events, including deaths.  Data suggested the drug might increase the risk of pain crises and “fatal events.”  billion.  

360

360

STAT

OCTOBER 5, 2022

Health tech companies and their backers are increasingly cautious as they brace for uncertain market conditions leading into the new year. But industry gatherings are in full swing, and we’re expecting lively debate about which digital health offerings will win out as investments and contracts sink below their pandemic peak.

247

247

STAT

APRIL 17, 2024

events per hour on the apnea-hypopnea index (AHI), a measure of the number of times breathing stops and becomes restricted while sleeping. events in patients on placebo, Lilly said in a press release Wednesday. That compares with a reduction of 5.3 Continue to STAT+ to read the full story…

363

363

STAT

JANUARY 9, 2024

In honor of JPM Week, you’re reading a special edition of our biotech newsletter, The Readout. To stay on top of the latest scoops and live reporting from the San Francisco conference,  join our newsletter list.

Drug Pricing 236

Drug Pricing Drug Development 236

STAT

FEBRUARY 19, 2024

The study looked into two cohorts of patients without active heart disease, 60% of whom were treated with statins, and found a strong association between a metabolic product of excess niacin and an increased risk of major adverse cardiovascular events such as a heart attack or stroke. Read the rest…

Diabetes 351

Diabetes 351